Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in Cyprus has been steadily developing over the past few years, with a growing demand for these drugs due to an aging population and an increase in chronic diseases.
Customer preferences: Patients in Cyprus have shown a preference for newer anti-coagulant drugs over traditional ones due to their perceived safety and efficacy. This trend is in line with the global market, where newer drugs such as direct oral anti-coagulants (DOACs) have been gaining popularity over traditional warfarin.
Trends in the market: The Anti-Coagulants market in Cyprus is expected to continue its growth trajectory due to the increasing prevalence of chronic diseases such as atrial fibrillation and deep vein thrombosis. Additionally, the rise in the aging population has led to a higher demand for anti-coagulant drugs. Another trend in the market is the increasing use of DOACs, which are expected to replace warfarin as the standard of care for anti-coagulation therapy.
Local special circumstances: One of the unique factors in the Cypriot market is the high prevalence of thalassemia, a genetic blood disorder that requires blood transfusions and can lead to iron overload. Patients with thalassemia are at a higher risk of developing blood clots, which increases the demand for anti-coagulant drugs. Additionally, Cyprus has a high prevalence of cardiovascular disease, which further drives the demand for these drugs.
Underlying macroeconomic factors: The Cypriot healthcare system has undergone significant reforms in recent years, which have led to increased access to healthcare services and drugs. The government has also implemented policies to encourage the use of generic drugs, which has led to cost savings for patients and the healthcare system. However, the economic recession of 2013 has led to a decrease in healthcare spending, which may impact the growth of the Anti-Coagulants market in the short term.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
